

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia (2018). Panduan Penatalaksanaan Kanker Payudara. <http://kanker.kemkes.go.id/guidelines/PPKPayudara.pdf> - Diakses Februari 2019.
2. International Agency for Research on Cancer (2018). Latest Global Cancer Data. https://www.iarc.fr/wp-content/uploads/2018/09/pr263_E.pdf - Diakses Februari 2019.
3. GLOBOCAN (2018). Cancer Fact Sheets. <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf>-Diakses Februari 2019.
4. Redig A. J and McAllister S. S. Breast cancer as a systemic disease: a view of metastasis. *Journal of Internal Medicine*. 2013; 274(2):113–126.
5. Vondeling GT, Menezes G L, Dvortsin EP, Jansman FGA, Konings IR, Postma MJ, et al. Burden of early, advanced and metastatic breast cancer in The Netherlands. *BMC Cancer*. 2018;18(1).
6. GLOBOCAN (2018). Cancer Population Fact Sheets in Indonesia. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf> - Diakses Februari 2019.
7. Kementerian Kesehatan Republik Indonesia (2015). Pusat Data dan Informasi Kanker. <http://www.depkes.go.id/resources/download/pusdatin/infodatin/info datin-kanker.pdf>- Diakses Februari 2019.
8. Kumar V, Cotran R, Robbin S. Buku ajar Patologi. Jakarta: Penerbit Buku Kedokteran EGC. 2007. hal 186.
9. Tsuji W, and Plock J A. Breast cancer metastasis. *Introduction to cancer metastasis*. Elsevier. 2017;13–31.
10. Geng B, Liang MM, Ye XB, and Zhao WY. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. *Molecular and Clinical Oncology*. 2014;3(1): 232–6.
11. Valic A, Milas I, Mayer L, Setic M, Matijevic V, Stanec M. Prognostic significance of CA 15-3 tumor marker in breast cancer patients. *Libri Oncol*. 2017; 45(1):1-8.

12. Fejzic H, Mujagic S, Azabagic S, Burina M. Tumor marker CA 15-3 in breast cancer patients. *Acta Medica Academica*. 2015; 44(1):39-46.
13. Hosseini S, Razmjoo S, Arvandi S, Barat T. CEA and CA 15-3 serum level in metastatic breast cancer and its correlation with distant metastasis. *Biomedical & Pharmacology Journal*. 2015; 8.
14. Sacher RA, McPherson RA. Tinjauan Klinis Hasil Pemeriksaan Laboratorium. Edisi 11. Jakarta: penerbit Buku Kedokteran EGC. 2002, hal 660.
15. Hashim Z. The significance of CA 15-3 in breast cancer patients and its relationship to HER-2 receptor status. *International Journal of Immunopathology And Pharmacology*. 2014; 27(1): 45-51.
16. Yerushalmi. R. Tumor marker in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. *Annals of Oncology*. 2012;23(2):338-345.
17. Sjamsuhidajat R, de Jong W. Buku Ajar Ilmu Bedah. Jakarta: Penerbit Buku Kedokteran EGC. Edisi ke-4. 2014.
18. Ramli M, Panigoro SS, Kurnia A. (Kelainan pada Payudara). Dalam: Ilmu Kandungan. Edisi ke-3. Jakarta: Bina Pustaka Sarwono Prawirohardjo. 2014. hal 402.
19. Sabiston C. Buku Ajar Bedah Sabiston. Jakarta: Penerbit Buku Kedokteran EGC. 2011.
20. What is Breast Cancer <https://ww5.komen.org/BreastCancer/AboutBreastCancer.html> - Diakses Februari 2019.
21. Gaol HL dan Briani F (Kanker Payudara) Dalam: Tanto C. Kapita Selekta. Edisi ke-4. Jakarta: Media Aesculapius. 2014 hal 231.
22. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. *Cell Biochemistry and Biophysics*. 2014; 72(2): 333–8.
23. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al .Risk factors and preventions of breast cancer. *International Journal of Biological Sciences*. 2017;13(11):1387–1397.

24. Brewer H, Jones M, Schoemaker M, Ashworth A, Swerdlow A. Family history and risk of breast cancer: An Analysis Accounting for Family Structure. *Breast Cancer Res Treat.* 2017;165:193-200.
25. Shah R. (2014). Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology.* 2014; 5(3): 283.
26. McKee T, and McKee JR. *Biochemistry in Perspective: Carcinogenesis.* Dalam (McKee T, McKee JR) *Biochemistry: The Molecular Basis of Life.* 5th Ed., Oxford University Press. 2013
27. Hanahan D and Weinberg RA. The Hallmarks of Cancer. *Cell.* 2000;100(1): 57–70.
28. McPhee SJ, Lingappa VR, Gamong WF, Lange JD. *Pathophysiology of disease an introduction to clinical medicine.* 2nded. Stamford: Appleton & Lange. 1995 .
29. Chabner BA, Lynch TJ, Longo DL. *Harrison's manual of Onkology,* New York: McGraw Hill. 2008.
30. Tumorigenesis Breast Cancer <https://www.hindawi.com/journals/bmri/2010/956897/fig1/> - Diakses Februari 2019.
31. Scarff-Bloom-Richardson (SBR) grade <https://oncologypro.esmo.org/content/download/125657/2375414/file/2017-ESMO-Preceptorship-Breast-New-Classification-Pathology-Subtypes-Paul-N-Mainwaring.pdf> - Diakses Februari 2019.
32. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol.* 2010 Jun;17(6):1471-4.
33. Bayo J, Castaño MA, Rivera F, Navarro F. Analysis of blood markers for early breast cancer diagnosis. *Clinical and Translational Oncology.* 2017; 20(4): 467–475.
34. ASCO Answers Breast Cancer (2018) <https://www.asco.org/practice-guidelines/quality-guidelines/guidelines> - Diakses Februari 2019.
35. Ultrasound in Breast Cancer <https://www.breastcancer.org/symptoms/testing/types/ultrasound-> Diakses Februari 2019.

36. Rubin E. Pathology: clinicopathology Foundations of Medicine in Rubin R and Strayer DS editors, 6th ed. Philadelphia: Lippincott Williams & Walkins, 2012.
37. Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, et al . (2015). Tissue invasion and metastasis: Molecular, biological and clinical perspectives. *Seminars in Cancer Biology*. 2015;35: S244–S275.
38. Jin X, and Mu P. Targeting breast cancer metastasis. *Breast cancer: Basic and Clinical Research*. *libertas academica*. 2015.
39. Marino N, Woditschka S, Reed L T, Nakayama J, Mayer M, Wetzel M, et al. Review: breast cancer metastasis, issue for the personalization of its prevention and treatment. *American Journal of Pathology*. 2013;183:1084-1095.
40. Kabel A M. Tumor markers of breast cancer: New prospectives. *Journal of Oncological Sciences*. 2017; 3(1):5–11.
41. Sunwoo H H, and Suresh MR. Cancer Markers. *The Immunoassay Handbook*. Elsevier. 2013; 833–856.
42. Choi JW, Moon BI, Lee JW, Kim HJ, Jin Y, Kim HJ. Use of CA 15-3 for screening breast cancer: An Antibody-lectin sandwich assay for detecting glycosylation of CA 15-3 in sera. *Oncology Report*. 2018; 40:145-154.
43. Aydin S. A Short History, Principles, and type of ELISA, and our Laboratory experience with peptide/protein analyses using ELISA. Elsevier. 2015;4-15.
44. Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, et al. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis sample. *British Journal of Cancer*. 2017;116:501-508.
45. Poznak CV, Somerfield MR, Bast R C, Cristofanilli M, Goetz M P, Gonzalez-Angulo A, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*. 2015;33(24): 2695–2704.
46. Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al . The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. *Clinica Chimica Acta*. 2017;470: 51–5.

47. Kresno SB. Ilmu Dasar Onkologi. Edisi ke-3. Jakarta: Balai Penerbit FK UI. 2011.
48. Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, and Di Gioia D. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer—A retrospective analysis of kinetics on 743 breast cancer patients. *Clinica Chimica Acta*. 2015;448: 228–231.
49. Stoenescu A, Herr D, Gerlinger C, Solomayer EF, Scholz C, Juhasz-Bozz I, et al. The potential role of preoperative serum cancer antigen CA 15-3 in the prognosis of breast cancer. *It. J. Gynaecol. Obstet*. 2015;27:115-9.
50. Dahlan, Sopiudin. Besar Sampel Dalam Penelitian Kedokteran dan Kesehatan. Jakarta: Salemba Medika. 2016.
51. Chen H, Zhou M, Tian W, Meng K, Hehai. Effect of Age on breast cancer patients prognoses: A population based study using SEER 18 database. *PLoS ONE*. 2016;10(11):1-11.
52. Rahmatya A, Khambri D, Mulyani H. Hubungan usia dengan gambaran klinikopatologi kanker payudara di bagian bedah RSUP Dr M Djamil Padang. *Jurnal Kesehatan Andalas*. 2015.
53. Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE. Breast cancer metastasis to the axillary lymph nodes: Are changes to the lymph node “soil” localized or systemic?. *Breast cancer, basic and clinical research*. 2017;1-5.
54. Rahman M, Mohammed S. breast cancer metastasis and the lymphatic system (review). *Oncology Letter*. 2015;10:1233-1239.
55. Obenauf AC, Massaue J. surviving at a distant organ specific metastasis. *Trends cancer*. 2016;1(1): 76-91.
56. Sanchez RE, Enriquez M, Castaneda V. Reliability of CA 15-3 in the following up of female patients with breast cancer carcinoma and bone metastasis. *Rev invest Clin*. 2003;55(4):412-8.
57. Lee JS, Park S, Park JM, Cho JH, Kim SI and Park BW. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancer. *Breast cancer res treat*. 2013;141:477-84.
58. Champion L. Breast Cancer recurrence diagnosis suspected on tumor marker rising. *Cancer*. 2011; 117(8): 1621-29.

59. Darlix A, Lamy PJ, Lopez-Crepes E, Braccini AL, Firmin N, Romieu G et al. serum HER2 extra-cellular domain, S100B and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016;16(1):1-14.
60. <https://www.breastcancer.org/research-news/do-young-women-have-worse-outcomes>. Diakses Juli 2019.
61. Sharma D, Singh G. Breast Cancer in young women: A Retrospective study from tertiary care center of north india. South Asian J Cancer. 2017;6(2):51-3.
62. El-Abd E, El-Sheikh M, Zaky S, Fayed W, El-Zoghby S. Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.. Cancer Biomarkers. 2017; 20(2):123-133.



